Rezlidhia (Olutasidenib) for Leukemia

Overview
Rezlidhia is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation (variation). A person must undergo an FDA-approved test to confirm the presence of the IDH1 mutation before starting treatment. Rezlidhia is also known by its drug name, olutasidenib.

Rezlidhia belongs to a class of drugs called IDH1 inhibitors. It works by blocking the activity of the mutated IDH1 enzyme, which is believed to reduce the production of abnormal cells in the bone marrow and help restore normal blood cell formation.

How do I take it?
Prescribing information states that Rezlidhia is taken orally as a capsule, typically twice daily. The medication should be taken on an empty stomach, at least one hour before or two hours after a meal. Rezlidhia should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Rezlidhia include increased levels of liver enzymes (aspartate aminotransferase and alanine aminotransferase), decreased potassium and sodium levels, increased alkaline phosphatase (an enzyme related to liver function), nausea, increased creatinine (a waste product in the blood), fatigue, joint pain, constipation, increased lymphocytes (a type of white blood cell), increased bilirubin (a substance in the blood linked to liver function), increased uric acid, difficulty breathing, fever, rash, increased lipase (an enzyme related to digestion), mucositis (mouth inflammation), diarrhea, and transaminitis (liver inflammation).

Rare but serious side effects may include severe liver toxicity, which requires monitoring of liver function tests. If hepatotoxicity occurs, treatment may need to be interrupted, reduced, or discontinued.

For more information about this treatment, visit:

Highlights of Prescribing Information: Rezlidhia (Olutasidenib) Capsules, for Oral Use – Rigel